Page 2 - Preliminary Phase News Today

Advanced lead candidate, MVP-S, in two global Phase 2B clinical trials and enhanced the scientific differentiation of the DPX platformObserved multiple complete clinical responses in relapsed/refractory DLBCL and expect to complete enrollment of stage one in the VITALIZE study in Q2 2023Accelerated enrollment of sta...

Preliminary Phase 1 clinical data from ARROS-1 Study presented at the 2022 EORTC-NCI-AACR Symposium supports best-in-class potential of NVL-520 for patients...

TEHRAN (Tasnim) – International Volleyball Federation’s website praised Iranian opposite spiker Amin Esmaeilnezhad.

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...

TEHRAN (Tasnim) – Reigning world champion Poland and reigning Asian continental champion Iran will meet in the 2022 Volleyball Nations league (VNL) semifinals on Thursday.

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO)...

(PLX AI) - Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses.• Preliminary Phase 2 study and a

Precigen Reports First Quarter 2021 Financial Results - Company on track to achieve stated 2021 milestones - - Initiated Phase 2 clinical trial of PRGN-2009 AdenoVerse™ immunotherapy - - Initiated Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy in patients with recurrent respiratory papillomatosis (RRP) - - Upcoming presentation at FOCIS Virtual Annual Meeting to provide clinical progress for AG019 ActoBiotics™ in Type 1 diabetes (T1D) - News provided by Share this article Shar...

Search jobs 08-Apr-2021 Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update Preliminary Phase 1b Data - Gedatolisib showed a potentially differentiated safety and tolerability profile - Corporate Update - Proceeds from first $15 million tranche increase cash-on-hand to $44 million - - Drug development capabilities ...

Trial Suggests Russias COVID-19 Vaccine is 91.6% Effective Feb 02, 2021 10:41 AM 873 views   Staff Writer Preliminary Phase 3 trial results from Russias Sputnik V vaccine shows that its 91.6% effective against symptomatic Covid-19 and 100% effective against severe and moderate disease.  The trial also found that the 2,144 people over the age of 60 tolerated the vaccine well, and the vaccine had a similar efficacy of 91.8%. Out of the total 19,866 participants, 16 cases of symptomatic Covid-19...